No question he is better endowed than his opponent and knows how to use it. Trump is looking better every day.
"doesn't appear more effective than Glemba:"
based on your psychic readings? Glemba is just now entering a Phase I trial in that indication.
If Glemba were to get the 34% response rate in third-line pts like this ADC did then CLDX would be delighted
There is really no risk to tender. If the Chinese firm makes a superior offer that ends up winning, the shares tendered to II-IV would be promptly returned to you.
Downside to not tendering is you will have to wait longer to get your money, 0ften as long as a few weeks.
"The only surprise from the FDA, as I have suggested, might be that the FDA grants a conditional approval of Rintega immediately upon learning the results of ACT IV"
That would indeed be a shocker. Never before has the FDA done anything even close to that!
That additional 3.8 million would be picked up by the new buyer and would not affect the amount shareholders received. If the board felt that the 0.85 Chinese offer was superior to the 0.81 domestic offer than 0.89 should suffice now.
"Anadigics now has a lifeline."
That would be lost if they sign a new deal with the Chinese company.
The main difference now is Company B needs to come back with a written, signed offer where before they just needed to convince the board they would have one.
One should not read too much into the language about what happens in the event of a better offer. The fiduciary duty outs are required by law and say nothing about the what the board was thinking.
'Why don't the chinese buyers get the last word? "
Because there already is in place an agreement permitting the buyer two days to match any superior offer. If the Chinese suitor had made the best offer back in December then they would be in that preferred position.